Cargando…
Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ―
Background: Circulating soluble neprilysin (sNEP) predicts outcome in heart failure (HF) patients with reduced ejection fraction (EF), but not in those with preserved EF. We examined sNEP in patients with hypertrophic cardiomyopathy (HCM), and their correlations with other biomarkers, cardiac functi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Circulation Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889477/ https://www.ncbi.nlm.nih.gov/pubmed/33693148 http://dx.doi.org/10.1253/circrep.CR-19-0034 |
_version_ | 1783652317879336960 |
---|---|
author | Yoshihisa, Akiomi Yokokawa, Tetsuro Ichijo, Yasuhiro Kimishima, Yusuke Kanno, Yuki Misaka, Tomofumi Sato, Takamasa Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Sugimoto, Koichi Kunii, Hiroyuki Takeishi, Yasuchika |
author_facet | Yoshihisa, Akiomi Yokokawa, Tetsuro Ichijo, Yasuhiro Kimishima, Yusuke Kanno, Yuki Misaka, Tomofumi Sato, Takamasa Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Sugimoto, Koichi Kunii, Hiroyuki Takeishi, Yasuchika |
author_sort | Yoshihisa, Akiomi |
collection | PubMed |
description | Background: Circulating soluble neprilysin (sNEP) predicts outcome in heart failure (HF) patients with reduced ejection fraction (EF), but not in those with preserved EF. We examined sNEP in patients with hypertrophic cardiomyopathy (HCM), and their correlations with other biomarkers, cardiac function, and clinical outcome. Methods and Results: We examined the associations between sNEP and the laboratory and echocardiography parameters in the HCM patients (n=93). Regarding the laboratory data, sNEP had a significant positive correlation with B-type natriuretic peptide (BNP; R=0.326, P=0.003), but not with troponin I. As for the echocardiographic parameters, sNEP negatively correlated with left ventricular EF (R=−0.283, P=0.009) and right ventricular fractional area change (R=−0.277, P=0.012), but not with left ventricular mass. Next, we prospectively followed up on the patients for cardiac events, including worsening HF or cardiac death, and all-cause mortality. On Kaplan-Meier analysis (mean follow-up, 1,021 days), the cardiac event rate and all-cause mortality were similar between the higher sNEP group (sNEP ≥median level of 1.43 ng/mL, n=46) and lower sNEP group (sNEP <1.43 ng/mL, n=47). On Cox proportional hazard analysis, sNEP was not a predictor of cardiac event or all-cause mortality. Conclusions: Soluble neprilysin appears to correlate with BNP and cardiac systolic function, but it is not significantly associated with prognosis in HCM patients. |
format | Online Article Text |
id | pubmed-7889477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Japanese Circulation Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-78894772021-03-09 Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― Yoshihisa, Akiomi Yokokawa, Tetsuro Ichijo, Yasuhiro Kimishima, Yusuke Kanno, Yuki Misaka, Tomofumi Sato, Takamasa Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Sugimoto, Koichi Kunii, Hiroyuki Takeishi, Yasuchika Circ Rep Original article Background: Circulating soluble neprilysin (sNEP) predicts outcome in heart failure (HF) patients with reduced ejection fraction (EF), but not in those with preserved EF. We examined sNEP in patients with hypertrophic cardiomyopathy (HCM), and their correlations with other biomarkers, cardiac function, and clinical outcome. Methods and Results: We examined the associations between sNEP and the laboratory and echocardiography parameters in the HCM patients (n=93). Regarding the laboratory data, sNEP had a significant positive correlation with B-type natriuretic peptide (BNP; R=0.326, P=0.003), but not with troponin I. As for the echocardiographic parameters, sNEP negatively correlated with left ventricular EF (R=−0.283, P=0.009) and right ventricular fractional area change (R=−0.277, P=0.012), but not with left ventricular mass. Next, we prospectively followed up on the patients for cardiac events, including worsening HF or cardiac death, and all-cause mortality. On Kaplan-Meier analysis (mean follow-up, 1,021 days), the cardiac event rate and all-cause mortality were similar between the higher sNEP group (sNEP ≥median level of 1.43 ng/mL, n=46) and lower sNEP group (sNEP <1.43 ng/mL, n=47). On Cox proportional hazard analysis, sNEP was not a predictor of cardiac event or all-cause mortality. Conclusions: Soluble neprilysin appears to correlate with BNP and cardiac systolic function, but it is not significantly associated with prognosis in HCM patients. The Japanese Circulation Society 2019-05-21 /pmc/articles/PMC7889477/ /pubmed/33693148 http://dx.doi.org/10.1253/circrep.CR-19-0034 Text en Copyright © 2019, THE JAPANESE CIRCULATION SOCIETY This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original article Yoshihisa, Akiomi Yokokawa, Tetsuro Ichijo, Yasuhiro Kimishima, Yusuke Kanno, Yuki Misaka, Tomofumi Sato, Takamasa Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Sugimoto, Koichi Kunii, Hiroyuki Takeishi, Yasuchika Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title | Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title_full | Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title_fullStr | Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title_full_unstemmed | Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title_short | Soluble Neprilysin ― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ― |
title_sort | soluble neprilysin ― cardiac function and outcome in hypertrophic cardiomyopathy ― |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889477/ https://www.ncbi.nlm.nih.gov/pubmed/33693148 http://dx.doi.org/10.1253/circrep.CR-19-0034 |
work_keys_str_mv | AT yoshihisaakiomi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT yokokawatetsuro solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT ichijoyasuhiro solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT kimishimayusuke solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT kannoyuki solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT misakatomofumi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT satotakamasa solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT oikawamasayoshi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT kobayashiatsushi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT yamakitakayoshi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT sugimotokoichi solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT kuniihiroyuki solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy AT takeishiyasuchika solubleneprilysincardiacfunctionandoutcomeinhypertrophiccardiomyopathy |